HR Execs on the Move

SpineFrontier

www.spinefrontier.com

 
SpineFrontier Inc. is a growing medical device company that designs, develops and markets implants and instruments that equip surgeons to perform the least invasive spine surgery. SpineFrontier`s innovative and disruptive technologies and techniques apply the Less Exposure Surgery (LES) philosophy to solve clinical problems and make the surgeries safer for the patient and easier for the surgeon. Surgeries can be done in an outpatient center and patients can be discharged same day with rapid recovery, due to less disruption of normal tissues and less time in surgery. We believe LESS is more. LESS time in treatment and recovery is MORE time in ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

SurgiTel

SurgiTel is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Frontier Dental Supply

Frontier Dental is a fast growing dental supply company headquartered in Toronto, Canada focused on providing dentists throughout North America with a bespoke shopping experience.

Conquest Imaging

Conquest Imaging is your one-stop source for all your diagnostic ultrasound needs. We provide the highest quality parts, probes, transducer repair, on-site service, technical training, reconditioned systems and free, 24x7x365 technical support.

Guided Delivery Systems

Guided Delivery Systems is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OXiGENE

OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.